Mankind Pharma delivered a robust first-quarter performance for FY27, reporting a consolidated net profit of ₹574 crore, a 29% increase from ₹445 crore in the corresponding period of the previous year. Revenue from operations rose 13% year-on-year to ₹4,031 crore, while EBITDA expanded by 25% to ₹1,060 crore. The results were driven by significant margin expansion, strong growth in domestic chronic therapies, and a 29% surge in international exports. The Board of Directors approved the unaudited financial results on July 30, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company’s operating leverage improved markedly, with EBITDA margins widening by 250 basis points (bps) to 26.3% from 23.8% in Q1FY26. Gross margins also improved by 230 bps to 72.8%, aided by sales price increases, a better mix from higher-margin chronic products, and a favorable base effect from inventory accruals in the prior year. Profit after tax (PAT) margins rose by 170 bps to 14.2%. Basic earnings per share (EPS) stood at ₹13.76, compared to ₹10.62 in the prior year quarter. Cash EPS, adjusted for non-cash items like depreciation and amortization, increased 20.8% YoY to ₹19.2.

Financial Performance Highlights

Standalone net profit was ₹558.49 crore, up from ₹415.27 crore in Q1FY25. Standalone revenue grew to ₹2,964.05 crore from ₹2,569.73 crore. Finance costs declined to ₹110 crore from ₹142 crore in Q4FY26, primarily due to the repayment of a ₹1,250 crore NCD tranche. However, the effective tax rate rose to 25.4% from 17.7% due to the expiry of tax exemptions for its Sikkim plant.

Segmental Breakdown and Business Updates

Domestic business (excluding Consumer Healthcare) grew 11% YoY to ₹3,180 crore, led by double-digit growth in the base business and strong momentum in chronic therapies. Chronic therapies contributed significantly, with cardiac drugs growing 19.4% and anti-diabetic drugs growing 12.7%. The company outperformed the industry prescription market (IPM) in key areas, including respiratory chronic (1.3x IPM growth) and cardiac (1.1x IPM growth). Specific brand performances included 21% growth in the Telmikind family, 30-31% growth in Lipirose and Statpure, and 29% growth in the Glizid brand family. Acute therapies recovered to 10.9% growth, broadly in line with IPM.

Exports surged 29% YoY to ₹605 crore, benefiting from new product launches in the US market, where Mankind has now launched 49 products. Currency movements contributed 12-13% to export growth. The Consumer Healthcare (CH) segment saw modest growth of 4% to ₹246 crore, impacted by the discontinuation of cash-and-carry business to protect general trade margins. However, it gained market share in key brands like Manforce and Prega News. Modern Trade and E-Commerce share increased to 15% from 11% in the prior year quarter, supported by 38% growth in that channel.

Strategic Initiatives and Outlook

Management highlighted a strategic shift towards chronic and specialty therapies, aiming to increase the chronic share to 50% in the medium term, up from 40% currently. The company launched a new division, Vistar, to scale lesser-focused brands. In innovation, Mankind partnered with Denovo Science for an AI-led drug discovery program and acquired the Rivotril brand from Roche, which is valued at ₹20-30 crore with potential for significant growth in the CNS segment.

Net debt reduced to ₹3,377 crore as of June 30, 2026, improving the net debt-to-adjusted EBITDA ratio to 0.9x from 1.1x in FY26. Management remains on track to repay acquisition-related debt by FY28. Capex spend increased to ₹198 crore (4.9% of revenue), lower than the full-year guidance of 6-7%. Working capital days increased to 52 days from 48 days due to higher inventory levels, which management expects to rationalize in coming quarters.

What the Numbers Show

The divergence between revenue growth (13%) and PAT growth (29%) underscores improved operational efficiency and successful cost management. The 250 bps expansion in EBITDA margins indicates a favorable product mix shift towards higher-margin chronic therapies. While gross margins are healthy at 72.8%, management cautioned about potential compression in subsequent quarters due to rising raw material prices and dollar fluctuations, though they maintain their full-year EBITDA guidance of 25.5-26.5%. Investors should note the ongoing income tax proceedings involving adjustments of ₹1,908.66 crore, which remain a contingent liability despite management’s confidence in their legal position.

Mankind Pharma recorded a notable block trade on the National Stock Exchange (NSE), with approximately 1,04,182 shares changing hands in a single transaction. The deal was executed at a price of ₹2,484.90 per share, aggregating to a total transaction value of ₹25.89 crores.

Block Trade Details

The following table summarises the key parameters of the block trade:

Block trades of this scale are typically executed by institutional investors or large market participants, and are carried out as a single transaction outside the regular order book to minimise market impact.